Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) has soared in after-hours trading after it provided an update on the status of its New Drug Application for Silenor for the treatment of insomnia and said that the FDA acknowledged that this resubmission would be considered a complete response. This also noted that no additional safety or efficacy data was needed and it now sees a decision from the FDA by March 21, 2010.
At 6:13 PM EST we have shares up literally over 100% at $2.56 (52-week range is $0.18 to $4.80). The last prints show that it traded 1.79 million shares in the after-hours session since the 4PM closing bell.
JON C. OGG
No comments:
Post a Comment